TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05276518

Intervention type: PROCEDURE
Intervention: Closure of cesarean section incision
Description: After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa.

Intervention type: PROCEDURE
Intervention: Closure of cesarean section incision
Description: After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa.
Study: NCT05801965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital solution for patients with Cancer
Description: A digital program that provides holistic lifestyle intervention as well as disease education.
Study: NCT05552469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: DFV890 Single Agent
Study: NCT05801965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care for patients with Cancer
Description: Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for patients with Cancer
Description: Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
Study: NCT05898360

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: time restricted eating

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal diet
Description: normal diet
Study: NCT05662007

Intervention type: OTHER
Description: no intervention

Intervention type: OTHER
Description: no intervention
Study: NCT06008821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine
Description: 60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral sham block with normal saline
Description: 10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)
Study: NCT06294782

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STereotactic Arhythmia Radioablation (STAR)
Description: STereotactic Arhythmia Radioablation (STAR)
Study: NCT04922970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: The interventon consist of 3 weekly, supervised group sessions for 4 months (16 weeks). The sessions consist of progressive full body strength training with a primary focus on lower extremity muscle strength. The leg exercises are leg press, knee extension and leg curl. In addition, participants will perform two upper body exercises. Physical assessment will take place immediately and monthly until 4 months.
Study: NCT05426772

Intervention type: OTHER
Group type: OTHER
Intervention: exercise and kinesiotaping
Description: Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate.
Study: NCT05042154

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WatchPAT
Description: The WatchPAT One can detect the presence of OSA based on measurement of peripheral arterial tone (PAT), pulse rate, oxygen saturation, actigraphy, snoring, and body position.
Study: NCT04669652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezo-ICSI
Description: During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
Study: NCT05695352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 1.5mg
Description: oral synthetic progesterone agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam 15 mg
Description: Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each tablet contains Calcium Carbonate 1000 mg
Study: NCT05363631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenomethionine (SLM)
Description: Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib is a small molecule tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a type of immunotherapy
Study: NCT05211362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sticky Bone and Repeated Injectable PRF (iPRF)
Description: The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone substitute
Description: The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
Study: NCT05762198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rezūm
Description: In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
Study: NCT05306275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use
Study: NCT04843137

Intervention type: DEVICE
Intervention: Cervical Transcutaneous Electrical Spinal Cord Stimulation
Description: Surface electrodes are placed over the cervical spinal cord. Constant current is delivery through these electrodes. Stimulation frequency and electrode configuration are manipulated, and outcome measures are recorded.
Study: NCT06530056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costovertebral Mobilization+Conventional Therapy
Description: Patient would receive costovertebral mobilization in side lying position for left 10th to 6th, in sitting position for right 10th to 2nd rib and in supine lying position for 1st rib.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises Frequency; 4 times/week for 3 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Therapy
Description: Electrotherapy:~• Hot Pack 10 minutes~Posture Corrective Exercises:~* Thoracic Rotation 10 rep/session~* Thoracic extension 10 rep/session~* Scapular retraction 5 rep/session~* Deep neck flexor Isometric 5 rep/session~Deep Breathing Exercises:~• Pursed lip breathing 10 repetition in one session
Study: NCT06355388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tVNS
Description: As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus, and a 10-minute stimulation will be initiated with a pulse width of 200 μs, a frequency of 30 Hz, and an intensity of one mA lower than the patient's sensitivity threshold.~As fort he mid-term phase, a device will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tVNS
Description: As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus for 10-minute but no current will be delivered.~As fort he mid-term phase, a device (configured to withhold power delivery) will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session.
Study: NCT05207306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of interfascial plane block
Description: In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way.
Study: NCT05593523

Intervention type: DRUG
Intervention: Indocyanine green (ICG)
Description: ICG is a well, known, FDA-approved dye
Study: NCT05593523

Intervention type: DRUG
Intervention: Indocyanine green (ICG)
Description: ICG is a well, known, FDA-approved dye

Intervention type: DEVICE
Intervention: OnLume
Description: The OnLume Clinical Imaging System (CIS), also known as the Asimov-MSK Imaging System, used in this study is a clinical fluorescence-guided imaging system.

Intervention type: DEVICE
Intervention: OnLume
Description: The OnLume Clinical Imaging System (CIS), also known as the Asimov-MSK Imaging System, used in this study is a clinical fluorescence-guided imaging system.
Study: NCT06417346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic TEP Repair
Description: Laparoscopic TEP Repair performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Technique (Lichtenstein)
Description: Open Technique (Lichtenstein) performed
Study: NCT05188430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device (Kaptufat®)
Description: 140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration: 3 tablets twice a day before the main meals
Study: NCT05309616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taltz
Description: Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
Study: NCT06173505

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vudalimab + Carboplatin + Pemetrexed
Description: Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab + Carboplatin + Pemetrexed
Description: Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous
Study: NCT05991427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)
Description: 2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Study: NCT06270355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk based screening
Description: Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk based screening
Description: Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
Study: NCT05847244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
Study: NCT05991427

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zoster Vaccine Recombinant, Adjuvanted (Shingrix)
Description: 2 doses of Shingrix vaccine on Day 0 and Month 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-VZV
Description: 2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Study: NCT05415852

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser
Study: NCT05380674

Intervention type: BEHAVIORAL
Intervention: The short questionnaire of healthy habits
Description: collects sociodemographic data, weight, height, and physical activity, self-reported.
Study: NCT04702217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
Study: NCT04809389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DelNS1-nCoV-RBD LAIV
Description: Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: 0.9% NaCl solution
Study: NCT06224621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endocardial Septal Radiofrequency Ablation
Description: Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
Study: NCT04719741

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial

Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial
Study: NCT05037786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infographic
Description: Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Powerpoint
Description: Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
Study: NCT05748327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcasite restorative material
Description: Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), conditioning with primer, mixing alcasite capsula, place restoration, polymerizing and finishing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulk fill glass hybrid restorative material
Description: Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), mixing bulk fill glass hybrid capsula, conditioning, place restoration, apply coating, polymerizing and finishing
Study: NCT06533462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiallergen powder
Description: OIT multiallergen powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiallergen powder
Description: OIT multiallergen powder.
Study: NCT04520776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAGUERA®C Cervical Disc Prosthesis
Description: surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobi-C® Cervical Disc
Description: surgery
Study: NCT05842967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: 120-µg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: 120-µg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06389513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV4
Description: 4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
Study: NCT06013904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Difficult PIV placement personnel
Description: Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-trained PEM Fellows
Description: US-trained PEM Fellows
Study: NCT04878497

Intervention type: DRUG
Intervention: Warfarin
Description: Initiation of warfarin, identified using prescription fill in pharmacy claims

Intervention type: DRUG
Intervention: Dabigatran
Description: Initiation of dabigatran, identified using prescription fill in pharmacy claims

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Initiation of rivaroxaban, identified using prescription fill in pharmacy claims

Intervention type: DRUG
Intervention: Apixaban
Description: Initiation of apixaban, identified using prescription fill in pharmacy claims

Intervention type: DRUG
Intervention: Edoxaban
Description: Initiation of edoxaban, identified using prescription fill in pharmacy claims
Study: NCT06049953

Intervention type: DRUG
Intervention: Antipsychotics
Description: Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.

Intervention type: DRUG
Intervention: Non-antipsychotic medication
Description: Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.

Intervention type: OTHER
Intervention: No Medication
Description: Non-psychotropic medications
Study: NCT05279508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make My Day - stroke prevention program
Description: A stroke prevention program within primary healthcare